Financing led by RA Capital Management with participation from Insight Partners, NVentures, Catalio Capital Management, Eli Lilly and Company, Gaingels, and Cooley LLP
Funds to support clinical development of lead programs and expansion of small molecule pipeline focused on high-value GPCR targets
BOSTON, Sept. 09, 2024 (GLOBE NEWSWIRE) -- Superluminal Medicines, Inc., “The Membrane Company” using generative biology, chemistry, and machine learning approaches to revolutionize the speed and accuracy of how medicines are created, today announced the closing of a $120 million Series A funding round. RA Capital Management led the investment, with participation from existing investors Insight Partners, NVentures (NVIDIA’s venture capital arm), and Gaingels. New investors Catalio Capital Management, Eli Lilly and Company, and Cooley LLP joined in the financing, and Diamantis Xylas, MD of Catalio joined the Board of Directors.
The funds will support the progression of Superluminal’s lead program into clinical development and increase the number of small molecule drug discovery programs focused on high-value G protein-coupled receptor (GPCR) targets. The company’s platform rapidly creates candidate-ready compounds by utilizing a unique combination of human understanding, generative biology, chemistry, machine learning, and proprietary big data infrastructure.
“We are grateful to have the continued support of our renowned seed investors and prominent new investors as we rapidly progress our existing high-value programs and expand our pipeline,” said Cony D'Cruz, CEO of Superluminal Medicines. “We are advancing six small molecule programs and continue to build a discovery platform to quickly and efficiently generate therapeutics for any membrane drug target.”
“We continue to be impressed by the speed at which Superluminal has progressed its existing programs for really challenging drug targets,” said Andrew Levin, MD, PhD, Partner and Managing Director at RA Capital Management. “Superluminal’s platform and team have demonstrated success, and we are pleased to continue to support the company’s further growth and development.”
Superluminal’s focus is on membrane receptors that mediate cell signaling and response processes fundamental to human physiology and constitute major classes of drug targets–including GPCRs, ion channels, and transporters. GPCRs are a large family of integral membrane proteins that are drug targets for ~35% of all approved drugs. Yet 70% of the more than 800 GPCRs are undrugged and only 138 have experimental active-state protein structures.
“Our approach allows us to interrogate proteins dynamically, exploring the variety of conformations a protein can adopt, which is critical to identifying specific disease states mediated by membrane receptors,” said Mr. D'Cruz. “By understanding and leveraging these dynamic properties, we can intervene positively within the natural context of the cell and the body.”
The company’s board of directors offers a wealth of industry expertise to guide Superluminal. The board includes Andrew Levin, MD, PhD, Partner and Managing Director at RA Capital Management; Dylan Morris PhD, Managing Director at Insight Partners; Diamantis Xylas MD, Partner and Co-Head of Investments at Catalio Capital Management and Cony D’Cruz, CEO of Superluminal Medicines.
About Superluminal Medicines Inc.
Superluminal Medicines is a generative biology and chemistry company developing a differentiated pipeline and revolutionizing the speed and accuracy of how medicine is created. The company’s platform creates candidate-ready compounds with unprecedented speed using a comprehensive combination of deep biology and chemistry expertise, machine learning, and proprietary big data infrastructure. The predict-design-test architecture accurately models protein shapes and designs highly selective compounds to target the precise structural change for therapeutic effect. Its discovery engine is powered by an industry-leading, pharmacokinetic and toxicology in silico prediction capability. The company’s proprietary pipeline validates its platform with initial programs focused on high-value GPCR targets. Based in Boston, the company is backed by a strong network of investors including RA Capital Management, Insight Partners, NVentures, Catalio Capital Management, Eli Lilly and Company, Gaingels, and Cooley LLP. For more, visit www.superluminalrx.com.
About RA Capital Management
RA Capital Management is a multi-stage investment manager dedicated to evidence-based investing in public and private healthcare, life sciences, and planetary health companies. RA Capital Management forms and funds innovative companies, from private seed rounds to public follow-on financings, allowing management teams to drive value creation from inception through commercialization and beyond. RA Capital Management's knowledge engine is guided by our TechAtlas internal research division, and its company creation team, RA Ventures (RAVen), offers experienced entrepreneurs a collaborative and comprehensive platform to explore the novel and the re-imagined. For more information, visit racap.com.
About Insight Partners
Insight Partners is a global software investor partnering with high-growth technology, software, and Internet startup and Scaleup companies that are driving transformative change in their industries. As of December 31, 2023, the firm has over $80B in regulatory assets under management. Insight Partners has invested in more than 800 companies worldwide and has seen over 55 portfolio companies achieve an IPO. Headquartered in New York City, Insight has offices in London, Tel Aviv, and Palo Alto. Insight's mission is to find, fund, and work successfully with visionary executives, providing them with the right-sized, right-time practical, hands-on software expertise along their growth journey, from their first investment to IPO. For more information on Insight and all its investments, visit www.insightpartners.com.
Catalio Capital
Catalio Capital Management, LP, is a multi-strategy life sciences investment firm focusing on breakthrough biomedical technology companies developing the next generation of drugs, devices, diagnostics, and data-driven insights. Catalio has partnered with over 45 world-renowned scientists with extensive academic and scientific achievements who have each also started well-established companies based on their research and to provide proprietary deal-flow and diligence to inform our investment decisions. The firm is headquartered in New York and has offices in London and Washington, DC. Learn more about Catalio Capital Management by visiting www.cataliocapital.com.
Media Contact
Janine McCargo
6 Degrees
jmccargo@6degreespr.com
